Renibus Therapeutics Receives FDA Orphan Drug Designation for Veverimer
Renibus Therapeutics® has announced that the FDA has granted Orphan Drug Designation to its investigational therapy veverimer for the treatment of anti-glomerular basement membrane (anti-GBM) disease—an ultra-rare, life-threatening autoimmune condition that causes acute kidney failure. This designation supports the development of treatments for diseases affecting fewer than 200,000 people in the U.S. and provides Renibus with key incentives, including tax credits for clinical trials, waived FDA fees, and the potential for seven years of market exclusivity upon approval.
Renibus Therapeutics Receives FDA Orphan Drug Designation for Veverimer